Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 25 | 2022 | 1051 | 1.620 |
Why?
|
Carcinoma, Squamous Cell | 19 | 2019 | 1075 | 1.540 |
Why?
|
Salivary Gland Neoplasms | 5 | 2019 | 66 | 1.320 |
Why?
|
Carcinoma, Mucoepidermoid | 2 | 2019 | 17 | 1.320 |
Why?
|
Otolaryngology | 2 | 2023 | 53 | 1.250 |
Why?
|
Chemoradiotherapy | 14 | 2022 | 301 | 1.030 |
Why?
|
Neoplasm Recurrence, Local | 13 | 2022 | 1305 | 0.940 |
Why?
|
Otolaryngologists | 1 | 2023 | 4 | 0.920 |
Why?
|
Actinomycosis | 1 | 2022 | 12 | 0.880 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2022 | 2434 | 0.870 |
Why?
|
Larynx | 1 | 2022 | 38 | 0.860 |
Why?
|
Oropharyngeal Neoplasms | 6 | 2022 | 118 | 0.830 |
Why?
|
Perforator Flap | 1 | 2020 | 12 | 0.750 |
Why?
|
Mouth Neoplasms | 7 | 2018 | 194 | 0.710 |
Why?
|
Paranasal Sinus Diseases | 2 | 2018 | 25 | 0.710 |
Why?
|
Gene Rearrangement | 2 | 2019 | 170 | 0.690 |
Why?
|
Papillomavirus Infections | 5 | 2022 | 239 | 0.670 |
Why?
|
Neoplasm Grading | 1 | 2019 | 356 | 0.630 |
Why?
|
Nose Diseases | 1 | 2017 | 10 | 0.620 |
Why?
|
Laryngeal Diseases | 2 | 2015 | 20 | 0.620 |
Why?
|
Nose Neoplasms | 1 | 2017 | 31 | 0.620 |
Why?
|
Nasal Cavity | 1 | 2017 | 91 | 0.590 |
Why?
|
Maxillary Sinus | 2 | 2018 | 26 | 0.590 |
Why?
|
Trans-Activators | 1 | 2019 | 429 | 0.570 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2016 | 24 | 0.550 |
Why?
|
Aspergillosis | 1 | 2016 | 41 | 0.540 |
Why?
|
Cementoma | 1 | 2015 | 2 | 0.540 |
Why?
|
Mandibular Neoplasms | 1 | 2015 | 24 | 0.530 |
Why?
|
Sarcoidosis | 1 | 2015 | 71 | 0.510 |
Why?
|
Papillomaviridae | 4 | 2022 | 153 | 0.500 |
Why?
|
Laryngeal Neoplasms | 5 | 2017 | 89 | 0.490 |
Why?
|
Female | 53 | 2023 | 44405 | 0.460 |
Why?
|
Sjogren's Syndrome | 3 | 2009 | 30 | 0.450 |
Why?
|
Humans | 72 | 2023 | 86281 | 0.450 |
Why?
|
Middle Aged | 43 | 2022 | 24957 | 0.450 |
Why?
|
Salivary Glands, Minor | 2 | 2009 | 9 | 0.450 |
Why?
|
Aged, 80 and over | 21 | 2020 | 6481 | 0.430 |
Why?
|
Biomarkers, Tumor | 2 | 2022 | 1461 | 0.420 |
Why?
|
Male | 50 | 2023 | 40860 | 0.410 |
Why?
|
Adult | 40 | 2023 | 25577 | 0.400 |
Why?
|
Airway Management | 1 | 2012 | 46 | 0.390 |
Why?
|
Carcinoma | 3 | 2022 | 434 | 0.370 |
Why?
|
Aged | 34 | 2020 | 18353 | 0.360 |
Why?
|
Placenta | 1 | 2011 | 173 | 0.360 |
Why?
|
Anesthesiology | 1 | 2012 | 156 | 0.360 |
Why?
|
Quinazolines | 4 | 2012 | 220 | 0.350 |
Why?
|
Hydroxyurea | 10 | 2022 | 239 | 0.350 |
Why?
|
Leukoplakia, Oral | 2 | 2023 | 11 | 0.350 |
Why?
|
Induction Chemotherapy | 6 | 2022 | 147 | 0.340 |
Why?
|
Disease-Free Survival | 15 | 2020 | 1203 | 0.330 |
Why?
|
Fluorouracil | 10 | 2022 | 556 | 0.310 |
Why?
|
Neck | 2 | 2020 | 100 | 0.300 |
Why?
|
Head | 2 | 2020 | 131 | 0.300 |
Why?
|
Radiotherapy, Intensity-Modulated | 5 | 2016 | 173 | 0.290 |
Why?
|
Clinical Competence | 1 | 2012 | 750 | 0.280 |
Why?
|
Radiotherapy Dosage | 11 | 2020 | 468 | 0.270 |
Why?
|
Anti-Bacterial Agents | 3 | 2022 | 739 | 0.270 |
Why?
|
Warts | 2 | 2019 | 11 | 0.260 |
Why?
|
Paclitaxel | 6 | 2022 | 460 | 0.260 |
Why?
|
ErbB Receptors | 4 | 2016 | 485 | 0.250 |
Why?
|
Tongue Neoplasms | 4 | 2018 | 50 | 0.250 |
Why?
|
Diagnosis, Differential | 4 | 2017 | 1562 | 0.250 |
Why?
|
Nasopharyngeal Neoplasms | 2 | 2016 | 47 | 0.250 |
Why?
|
Treatment Outcome | 17 | 2022 | 7949 | 0.230 |
Why?
|
Antineoplastic Agents | 6 | 2012 | 2351 | 0.230 |
Why?
|
Alphapapillomavirus | 2 | 2021 | 45 | 0.230 |
Why?
|
Oral and Maxillofacial Surgeons | 1 | 2023 | 4 | 0.230 |
Why?
|
Irritants | 1 | 2022 | 4 | 0.220 |
Why?
|
Neoplasm Staging | 12 | 2016 | 1932 | 0.220 |
Why?
|
Pharynx | 1 | 2022 | 45 | 0.220 |
Why?
|
Re-Irradiation | 1 | 2022 | 15 | 0.220 |
Why?
|
HIV-1 | 1 | 2023 | 163 | 0.210 |
Why?
|
Laryngostenosis | 1 | 2021 | 16 | 0.200 |
Why?
|
Tracheal Stenosis | 1 | 2021 | 23 | 0.200 |
Why?
|
Drug Monitoring | 1 | 2022 | 118 | 0.200 |
Why?
|
DNA, Viral | 1 | 2022 | 265 | 0.200 |
Why?
|
Carcinoma, Papillary, Follicular | 1 | 2020 | 13 | 0.200 |
Why?
|
Respiratory System | 1 | 2021 | 116 | 0.190 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2022 | 69 | 0.190 |
Why?
|
Anti-HIV Agents | 1 | 2023 | 149 | 0.190 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2019 | 348 | 0.190 |
Why?
|
Follow-Up Studies | 13 | 2019 | 3616 | 0.190 |
Why?
|
ras Proteins | 1 | 2020 | 128 | 0.180 |
Why?
|
Lymph Nodes | 2 | 2016 | 530 | 0.180 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2020 | 137 | 0.180 |
Why?
|
Smoking | 3 | 2014 | 605 | 0.180 |
Why?
|
Practice Guidelines as Topic | 2 | 2017 | 1030 | 0.180 |
Why?
|
Risk Factors | 8 | 2019 | 5397 | 0.180 |
Why?
|
Cetuximab | 2 | 2019 | 113 | 0.180 |
Why?
|
United States | 7 | 2023 | 6637 | 0.180 |
Why?
|
Young Adult | 6 | 2022 | 5961 | 0.180 |
Why?
|
Thyroid Neoplasms | 2 | 2020 | 406 | 0.180 |
Why?
|
Prognosis | 9 | 2022 | 3669 | 0.170 |
Why?
|
Radiation Dosage | 1 | 2020 | 227 | 0.170 |
Why?
|
Arteries | 1 | 2020 | 174 | 0.170 |
Why?
|
Heterocyclic Compounds | 1 | 2019 | 17 | 0.170 |
Why?
|
Maximum Tolerated Dose | 4 | 2022 | 270 | 0.170 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2019 | 47 | 0.170 |
Why?
|
Retrospective Studies | 15 | 2018 | 8431 | 0.170 |
Why?
|
Combined Modality Therapy | 9 | 2016 | 1680 | 0.170 |
Why?
|
Bone Cysts, Aneurysmal | 1 | 2018 | 7 | 0.170 |
Why?
|
Receptors, CXCR4 | 1 | 2019 | 44 | 0.170 |
Why?
|
Lip | 2 | 2009 | 16 | 0.170 |
Why?
|
Precancerous Conditions | 2 | 2016 | 196 | 0.170 |
Why?
|
Carboplatin | 4 | 2022 | 286 | 0.160 |
Why?
|
Dental Alloys | 1 | 2018 | 5 | 0.160 |
Why?
|
Orthodontic Appliances | 1 | 2018 | 7 | 0.160 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2018 | 63 | 0.160 |
Why?
|
Deglutition | 3 | 2020 | 73 | 0.160 |
Why?
|
Erlotinib Hydrochloride | 2 | 2016 | 90 | 0.160 |
Why?
|
Inflammation | 2 | 2017 | 913 | 0.160 |
Why?
|
Adolescent | 7 | 2022 | 8968 | 0.160 |
Why?
|
Child | 6 | 2019 | 6913 | 0.160 |
Why?
|
Glottis | 1 | 2017 | 11 | 0.150 |
Why?
|
Mammary Analogue Secretory Carcinoma | 1 | 2017 | 4 | 0.150 |
Why?
|
Surveys and Questionnaires | 2 | 2023 | 2495 | 0.150 |
Why?
|
Bone Marrow | 1 | 2019 | 434 | 0.150 |
Why?
|
Life Style | 1 | 2018 | 188 | 0.150 |
Why?
|
Hypopharyngeal Neoplasms | 2 | 2011 | 15 | 0.150 |
Why?
|
Fibrosis | 1 | 2017 | 202 | 0.140 |
Why?
|
Prospective Studies | 7 | 2022 | 4194 | 0.140 |
Why?
|
Transcriptome | 1 | 2020 | 574 | 0.140 |
Why?
|
Professionalism | 1 | 2016 | 24 | 0.140 |
Why?
|
Time Factors | 4 | 2019 | 5198 | 0.140 |
Why?
|
Neoplasm Invasiveness | 3 | 2016 | 551 | 0.130 |
Why?
|
Fibroma, Ossifying | 1 | 2015 | 5 | 0.130 |
Why?
|
Anticarcinogenic Agents | 1 | 2016 | 70 | 0.130 |
Why?
|
Guideline Adherence | 1 | 2017 | 222 | 0.130 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 1196 | 0.130 |
Why?
|
Pleural Neoplasms | 1 | 2017 | 188 | 0.130 |
Why?
|
Premedication | 1 | 1995 | 54 | 0.130 |
Why?
|
Simulation Training | 1 | 2016 | 88 | 0.130 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 1671 | 0.130 |
Why?
|
Cerebellopontine Angle | 1 | 1994 | 7 | 0.120 |
Why?
|
HIV Infections | 1 | 2023 | 768 | 0.120 |
Why?
|
Ulnar Nerve | 1 | 1994 | 6 | 0.120 |
Why?
|
Neuroma, Acoustic | 1 | 1994 | 20 | 0.120 |
Why?
|
Tumor Virus Infections | 1 | 2014 | 81 | 0.120 |
Why?
|
Neuromuscular Blocking Agents | 1 | 1994 | 29 | 0.120 |
Why?
|
Facial Nerve | 1 | 1994 | 33 | 0.120 |
Why?
|
Aminolevulinic Acid | 1 | 2013 | 21 | 0.120 |
Why?
|
Photosensitizing Agents | 1 | 2013 | 48 | 0.120 |
Why?
|
Biopsy | 4 | 2009 | 1160 | 0.110 |
Why?
|
Monitoring, Intraoperative | 1 | 1994 | 109 | 0.110 |
Why?
|
Mouth | 2 | 2011 | 48 | 0.110 |
Why?
|
Photochemotherapy | 1 | 2013 | 97 | 0.110 |
Why?
|
Pain | 1 | 2015 | 389 | 0.110 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2012 | 94 | 0.110 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 368 | 0.110 |
Why?
|
Radiotherapy | 2 | 2011 | 326 | 0.100 |
Why?
|
Survival Analysis | 5 | 2018 | 1536 | 0.100 |
Why?
|
Lymph Node Excision | 1 | 2013 | 211 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 589 | 0.100 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2011 | 35 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2012 | 468 | 0.100 |
Why?
|
Research Design | 2 | 2013 | 594 | 0.100 |
Why?
|
Tracheotomy | 1 | 2011 | 18 | 0.100 |
Why?
|
Organ Preservation | 1 | 2011 | 81 | 0.100 |
Why?
|
Deglutition Disorders | 2 | 2011 | 115 | 0.100 |
Why?
|
Survival Rate | 4 | 2019 | 1856 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 2267 | 0.090 |
Why?
|
Speech | 1 | 2010 | 84 | 0.090 |
Why?
|
Brain Diseases | 1 | 2011 | 180 | 0.090 |
Why?
|
Airway Obstruction | 1 | 2011 | 109 | 0.090 |
Why?
|
Agammaglobulinemia | 1 | 2010 | 20 | 0.090 |
Why?
|
Vocal Cords | 1 | 2009 | 25 | 0.090 |
Why?
|
Developmental Disabilities | 1 | 2011 | 194 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 4 | 2013 | 859 | 0.090 |
Why?
|
Quality of Life | 3 | 2012 | 1575 | 0.090 |
Why?
|
Emergency Medical Services | 1 | 2012 | 209 | 0.090 |
Why?
|
Cohort Studies | 5 | 2018 | 2759 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2009 | 407 | 0.080 |
Why?
|
Radiotherapy, High-Energy | 1 | 2008 | 49 | 0.080 |
Why?
|
Confidence Intervals | 4 | 2018 | 228 | 0.080 |
Why?
|
Genomics | 1 | 2014 | 710 | 0.080 |
Why?
|
Neck Dissection | 4 | 2010 | 65 | 0.080 |
Why?
|
Enteral Nutrition | 2 | 2020 | 102 | 0.080 |
Why?
|
Myelitis, Transverse | 1 | 2008 | 10 | 0.080 |
Why?
|
Skin | 1 | 2012 | 554 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2011 | 252 | 0.080 |
Why?
|
Submandibular Gland Diseases | 1 | 2008 | 9 | 0.080 |
Why?
|
Military Personnel | 1 | 2009 | 85 | 0.080 |
Why?
|
Neuromyelitis Optica | 1 | 2008 | 22 | 0.080 |
Why?
|
Aortic Aneurysm | 1 | 1988 | 80 | 0.080 |
Why?
|
Neoadjuvant Therapy | 2 | 2012 | 315 | 0.080 |
Why?
|
Risk Assessment | 5 | 2016 | 2253 | 0.080 |
Why?
|
Fatal Outcome | 2 | 2019 | 293 | 0.080 |
Why?
|
Taxoids | 1 | 2007 | 129 | 0.070 |
Why?
|
Sinus Thrombosis, Intracranial | 1 | 2006 | 13 | 0.070 |
Why?
|
DNA | 1 | 2012 | 1293 | 0.070 |
Why?
|
Tinnitus | 1 | 2006 | 21 | 0.070 |
Why?
|
Incidence | 3 | 2018 | 1568 | 0.070 |
Why?
|
Headache | 1 | 2006 | 73 | 0.070 |
Why?
|
Antibodies, Monoclonal | 2 | 2010 | 1376 | 0.070 |
Why?
|
Prodrugs | 2 | 1996 | 46 | 0.070 |
Why?
|
Drug Administration Schedule | 4 | 2016 | 916 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2019 | 1958 | 0.070 |
Why?
|
Drug Therapy, Combination | 3 | 1999 | 893 | 0.070 |
Why?
|
Infant, Newborn | 1 | 2011 | 2369 | 0.070 |
Why?
|
Cisplatin | 2 | 2022 | 612 | 0.060 |
Why?
|
Bevacizumab | 3 | 2011 | 281 | 0.060 |
Why?
|
Pregnancy | 1 | 2011 | 2885 | 0.060 |
Why?
|
Adenocarcinoma | 1 | 2011 | 1160 | 0.060 |
Why?
|
Gastroesophageal Reflux | 2 | 2009 | 117 | 0.060 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2017 | 104 | 0.060 |
Why?
|
Lamivudine | 1 | 2023 | 13 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2010 | 291 | 0.060 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2023 | 26 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 2 | 2011 | 2594 | 0.060 |
Why?
|
Remission Induction | 2 | 2016 | 722 | 0.050 |
Why?
|
Internship and Residency | 1 | 2012 | 1001 | 0.050 |
Why?
|
Immunohistochemistry | 3 | 2017 | 1752 | 0.050 |
Why?
|
Alcohol Drinking | 2 | 2018 | 264 | 0.050 |
Why?
|
Gene Expression Profiling | 2 | 2020 | 1381 | 0.050 |
Why?
|
Retreatment | 2 | 2012 | 107 | 0.050 |
Why?
|
Albumins | 1 | 2022 | 133 | 0.050 |
Why?
|
Pulmonary Surgical Procedures | 1 | 2021 | 8 | 0.050 |
Why?
|
RNA, Viral | 1 | 2023 | 327 | 0.050 |
Why?
|
Receptor, Endothelin A | 1 | 2021 | 22 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2013 | 173 | 0.050 |
Why?
|
Respiratory Function Tests | 1 | 2021 | 136 | 0.050 |
Why?
|
Endothelial Growth Factors | 1 | 2001 | 55 | 0.050 |
Why?
|
Lymphokines | 1 | 2001 | 76 | 0.050 |
Why?
|
Constriction, Pathologic | 1 | 2021 | 212 | 0.050 |
Why?
|
Antibodies, Monoclonal, Humanized | 3 | 2011 | 929 | 0.050 |
Why?
|
Periodontal Diseases | 1 | 2000 | 9 | 0.050 |
Why?
|
Radiography | 2 | 2014 | 812 | 0.050 |
Why?
|
Lymphoid Tissue | 1 | 2000 | 57 | 0.050 |
Why?
|
Bronchoscopy | 1 | 2021 | 152 | 0.050 |
Why?
|
Hyperplasia | 1 | 2000 | 148 | 0.050 |
Why?
|
Disease Progression | 2 | 2017 | 1531 | 0.040 |
Why?
|
Carcinoma, Papillary | 1 | 2001 | 158 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2022 | 751 | 0.040 |
Why?
|
Clindamycin | 2 | 1999 | 13 | 0.040 |
Why?
|
Cefuroxime | 2 | 1996 | 3 | 0.040 |
Why?
|
Tonsillectomy | 1 | 1999 | 30 | 0.040 |
Why?
|
Benzylamines | 1 | 2019 | 16 | 0.040 |
Why?
|
Patient-Centered Care | 1 | 2021 | 202 | 0.040 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2019 | 19 | 0.040 |
Why?
|
Aortic Rupture | 2 | 1990 | 55 | 0.040 |
Why?
|
Bone Marrow Examination | 1 | 2019 | 48 | 0.040 |
Why?
|
Patient Care Team | 1 | 2021 | 280 | 0.040 |
Why?
|
Antibiotic Prophylaxis | 1 | 1999 | 69 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 429 | 0.040 |
Why?
|
Primary Myelofibrosis | 1 | 2019 | 55 | 0.040 |
Why?
|
Oral Health | 1 | 2018 | 10 | 0.040 |
Why?
|
Double-Blind Method | 3 | 2016 | 1822 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 11 | 0.040 |
Why?
|
Myoepithelioma | 1 | 2017 | 11 | 0.040 |
Why?
|
Metals | 1 | 2018 | 90 | 0.040 |
Why?
|
Laryngectomy | 1 | 2017 | 26 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2017 | 24 | 0.040 |
Why?
|
Surgical Wound Infection | 2 | 1999 | 183 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2011 | 997 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2009 | 307 | 0.040 |
Why?
|
Parotid Gland | 1 | 2017 | 31 | 0.040 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2017 | 62 | 0.040 |
Why?
|
Mutation | 2 | 2020 | 3952 | 0.040 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2017 | 128 | 0.040 |
Why?
|
Biomarkers | 1 | 2023 | 1709 | 0.040 |
Why?
|
Probability | 2 | 2008 | 355 | 0.040 |
Why?
|
Translocation, Genetic | 1 | 2017 | 265 | 0.040 |
Why?
|
Otitis Media | 1 | 1996 | 18 | 0.030 |
Why?
|
Pyrazoles | 1 | 2017 | 153 | 0.030 |
Why?
|
Everolimus | 1 | 2016 | 40 | 0.030 |
Why?
|
Loss of Heterozygosity | 1 | 2016 | 85 | 0.030 |
Why?
|
Otitis Media with Effusion | 1 | 1995 | 6 | 0.030 |
Why?
|
Analgesics, Opioid | 1 | 2020 | 411 | 0.030 |
Why?
|
Cutaneous Fistula | 1 | 1995 | 11 | 0.030 |
Why?
|
Cellulitis | 1 | 1995 | 19 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2017 | 3347 | 0.030 |
Why?
|
Cephalosporins | 1 | 1995 | 23 | 0.030 |
Why?
|
Pyridines | 1 | 2017 | 309 | 0.030 |
Why?
|
Dissection | 1 | 1995 | 42 | 0.030 |
Why?
|
Human papillomavirus 18 | 1 | 2014 | 16 | 0.030 |
Why?
|
Sex Factors | 1 | 2018 | 1053 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 1995 | 153 | 0.030 |
Why?
|
Human papillomavirus 16 | 1 | 2014 | 38 | 0.030 |
Why?
|
Protein Interaction Maps | 1 | 2014 | 48 | 0.030 |
Why?
|
Drug Costs | 1 | 1995 | 62 | 0.030 |
Why?
|
Administration, Oral | 1 | 2016 | 683 | 0.030 |
Why?
|
Hospital Costs | 1 | 1995 | 104 | 0.030 |
Why?
|
Electromyography | 1 | 1994 | 183 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2017 | 589 | 0.030 |
Why?
|
Societies, Medical | 1 | 2017 | 572 | 0.030 |
Why?
|
Clavulanic Acids | 3 | 1999 | 3 | 0.030 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 3 | 1999 | 4 | 0.030 |
Why?
|
Amoxicillin | 3 | 1999 | 13 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2014 | 171 | 0.030 |
Why?
|
Age Factors | 1 | 2018 | 1842 | 0.030 |
Why?
|
Electric Stimulation | 1 | 1994 | 347 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2013 | 156 | 0.030 |
Why?
|
Rabbits | 1 | 1994 | 636 | 0.030 |
Why?
|
Platinum | 1 | 2012 | 63 | 0.030 |
Why?
|
Phenotype | 1 | 2019 | 2375 | 0.030 |
Why?
|
Aorta, Abdominal | 2 | 1990 | 60 | 0.030 |
Why?
|
Practice Patterns, Physicians' | 1 | 2017 | 578 | 0.030 |
Why?
|
Organ Sparing Treatments | 1 | 2011 | 36 | 0.030 |
Why?
|
Length of Stay | 1 | 1995 | 697 | 0.030 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 176 | 0.030 |
Why?
|
Supraglottitis | 1 | 2011 | 3 | 0.030 |
Why?
|
Pemetrexed | 1 | 2011 | 76 | 0.020 |
Why?
|
Glutamates | 1 | 2011 | 89 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2012 | 236 | 0.020 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2011 | 155 | 0.020 |
Why?
|
Leucovorin | 1 | 2010 | 218 | 0.020 |
Why?
|
Genetic Therapy | 1 | 2012 | 342 | 0.020 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2012 | 276 | 0.020 |
Why?
|
Osteoradionecrosis | 1 | 2010 | 18 | 0.020 |
Why?
|
Guanine | 1 | 2011 | 208 | 0.020 |
Why?
|
Interferon-alpha | 1 | 2010 | 233 | 0.020 |
Why?
|
Camptothecin | 1 | 2010 | 189 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2011 | 237 | 0.020 |
Why?
|
Postoperative Period | 1 | 2010 | 303 | 0.020 |
Why?
|
Laryngoscopy | 1 | 2009 | 44 | 0.020 |
Why?
|
Siblings | 1 | 2010 | 111 | 0.020 |
Why?
|
Treatment Failure | 1 | 2010 | 284 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2009 | 188 | 0.020 |
Why?
|
Postoperative Complications | 1 | 1999 | 2183 | 0.020 |
Why?
|
Transforming Growth Factor alpha | 1 | 2009 | 50 | 0.020 |
Why?
|
Syndrome | 1 | 2010 | 446 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2009 | 362 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 81 | 0.020 |
Why?
|
Bone Marrow Cells | 1 | 2010 | 253 | 0.020 |
Why?
|
Arteriosclerosis | 1 | 1988 | 113 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2010 | 1014 | 0.020 |
Why?
|
Bacterial Infections | 1 | 2010 | 181 | 0.020 |
Why?
|
Hypersensitivity | 1 | 2009 | 153 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2012 | 1056 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2009 | 480 | 0.020 |
Why?
|
Regression Analysis | 1 | 2009 | 595 | 0.020 |
Why?
|
Autoantibodies | 1 | 2008 | 267 | 0.020 |
Why?
|
Cranial Sinuses | 1 | 2006 | 15 | 0.020 |
Why?
|
Odds Ratio | 1 | 2008 | 677 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2010 | 532 | 0.020 |
Why?
|
Blood Vessel Prosthesis | 1 | 1988 | 228 | 0.020 |
Why?
|
Comorbidity | 1 | 2009 | 943 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 1988 | 435 | 0.020 |
Why?
|
Cerebrovascular Circulation | 1 | 2006 | 212 | 0.020 |
Why?
|
Prevalence | 1 | 2008 | 1239 | 0.020 |
Why?
|
Coronary Artery Disease | 1 | 1988 | 347 | 0.020 |
Why?
|
Signal Transduction | 1 | 2014 | 3233 | 0.010 |
Why?
|
Preoperative Care | 1 | 2006 | 390 | 0.010 |
Why?
|
Algorithms | 1 | 2011 | 1828 | 0.010 |
Why?
|
Registries | 1 | 2006 | 702 | 0.010 |
Why?
|
Asthma | 1 | 2009 | 947 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2001 | 56 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2006 | 1801 | 0.010 |
Why?
|
Ticarcillin | 1 | 1999 | 1 | 0.010 |
Why?
|
Mouthwashes | 1 | 1999 | 5 | 0.010 |
Why?
|
Ampicillin | 1 | 1999 | 15 | 0.010 |
Why?
|
Administration, Topical | 1 | 1999 | 94 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 1999 | 243 | 0.010 |
Why?
|
Infant | 2 | 1996 | 3036 | 0.010 |
Why?
|
Child, Preschool | 2 | 1996 | 3608 | 0.010 |
Why?
|
Pilot Projects | 1 | 1999 | 837 | 0.010 |
Why?
|
Animals | 2 | 1994 | 26518 | 0.010 |
Why?
|
Suspensions | 1 | 1996 | 6 | 0.010 |
Why?
|
Bacteria | 1 | 1999 | 445 | 0.010 |
Why?
|
Acute Disease | 1 | 1996 | 824 | 0.010 |
Why?
|
Back Pain | 1 | 1990 | 42 | 0.010 |
Why?
|
Hematoma | 1 | 1990 | 104 | 0.010 |
Why?
|
6-Ketoprostaglandin F1 alpha | 1 | 1988 | 5 | 0.010 |
Why?
|
Microscopy, Electron, Scanning | 1 | 1988 | 135 | 0.010 |
Why?
|
Polytetrafluoroethylene | 1 | 1988 | 74 | 0.010 |
Why?
|
Jugular Veins | 1 | 1988 | 69 | 0.010 |
Why?
|
Microcirculation | 1 | 1988 | 103 | 0.000 |
Why?
|
Omentum | 1 | 1988 | 71 | 0.000 |
Why?
|
Dogs | 1 | 1988 | 684 | 0.000 |
Why?
|
Aorta | 1 | 1988 | 280 | 0.000 |
Why?
|
Thrombosis | 1 | 1988 | 296 | 0.000 |
Why?
|